ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
|Articles|May 9, 2012
Jawboning by HHS Doesn't Scare Insurers
Advertisement
The Department of Health and Human Services isn’t that much of a bully, it turns out.
Health insurers flagged by the department for “unreasonable” premium hikes are refusing to back down in the first year of HHS’s new rate review authority.
Read the full story:
Source: Politico
The health reform law gave HHS the power to scrutinize “unreasonable” rate hikes in states that didn’t have robust review programs. But “scrutiny” doesn’t give the department power to actually block the rates from going into effect.
Advertisement
Related to this article
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
2
FDA Approves First Treatment for Sanfilippo Syndrome Type A
3
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
4
Lung Cancer Progress Drives Down US Cancer Death Rates
5